drugset / Trial / NCT05556343

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05556343

Phase 2 Terminated 18 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)

Timeline

Start
2023-01-18
Primary completion
2024-08-19
Completion
2025-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject DELOCAMTEN Small molecule

Indications

No indication recorded.